Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04795206 · ClinicalTrials.gov registry record
Natural Disease Progression in Participants With Choroideremia
A clinical trial of Choroideremia, sponsored by Biogen.
- Completed
- Registry status
- 1,178
- Enrollment target
- 1
- Study location
NCT04795206: Completed study of Choroideremia, sponsored by Biogen.
NCT04795206 is a study of Choroideremia that has completed, run by Biogen. The registered enrollment target is 1,178 participants, below the 2,966-participant average among 7 other Choroideremia trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04795206, a study of Choroideremia, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 1,178 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to quantify disease progression measured by best corrected visual acuity (BCVA) in the real-world setting among Choroideremia (CHM) participants. The secondary objectives are to describe demographic and baseline clinical characteristics among CHM participants and to match CHM participants in the Intelligent Research in Sight (IRIS®) Registry to Biogen's investigator sponsored trial (IST) study population using propensity score matching.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (1)
California
- Research Site - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,178 participants |
| Start Date | 2020-08-26 |
| Est. Completion | 2021-08-10 |
What the finished NCT04795206 record still lists
NCT04795206 is an observational study that tracks outcomes without assigning an intervention. Its 1,178 participants enrollment target places it among the larger protocols in the corpus, below the 2,966-participant average among 7 other Choroideremia trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Choroideremia appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT04795206 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04795206 about?
NCT04795206 is a clinical study titled "Natural Disease Progression in Participants With Choroideremia". The primary objective of this study is to quantify disease progression measured by best corrected visual acuity (BCVA) in the real-world setting among Choroideremia (CHM) participants. The secondary objectives are to describe demographic and baseline clinical characteristics among CHM participants a...
What is the current status of trial NCT04795206?
This trial is currently completed. The enrollment target is 1,178 participants. The study started on 2020-08-26. Estimated completion is 2021-08-10.
What conditions does trial NCT04795206 study?
This clinical trial studies the following conditions: Choroideremia.
What interventions are being tested in trial NCT04795206?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT04795206?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04795206 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Choroideremia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
High Resolution Retinal Imaging
RECRUITING
-
Inherited Retinal Degenerative Disease Registry
RECRUITING
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
-
Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia
ACTIVE NOT RECRUITING · Phase 1
-
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05688436 · 1,178 participants
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
- NCT06931275 · 1,178 participants · NA
Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes
- NCT06133322 · 1,176 participants · NA
Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)
- NCT07286058 · 1,182 participants · Phase 3
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI